The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
For World AIDS Day, read about stigma, criminalization and more >>
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

AIDS Clinical Research Projects

Fall 1996

Shared Medical Research


Study to test the effectiveness of oral hydroxyurea. Patients will be randomized to receive hydroxyurea alone vs. hydroxyurea + ddI + d4T vs. hydroxyurea + ddI. Patients may not have active opportunistic infections.

AIDS Research Alliance


Phase I study of the therapeutic vaccine HGP-30, a synthetic peptide subunit of HIV antigen p17. Use of approved antivirals other than protease inhibitors allowed. Patients must have T-cell count between 50 and 750. Sergio Codina or Corie Castro.

Pacific Oaks Research

Viracept/Protease Inhibitor

One year study. All participants will receive open-label Viracept. Must be on antiretroviral therapy and have no prior use of protease inhibitors.

Adefovir Dipivoxil

48 week study of adefovir dipivoxil, a new type of anti-HIV drug that is taken once daily. Participants must currently be tolerating any approved anti-HIV therapy.


Studies for O.I.'s

A wide variety of clinical Trials are open to women; Prevention and Treatment studies for O.I.'s

La Escuela de asistencia social en la U.S.C. esta llevando a cabo una encuesta de encuesta es completamente confidencial, y se paga $20. llame al 213.740.0299

Kraus Medical Partners

Salk Vaccine

Enrolling for Salk Vaccine trial.

UCLA Research

ACTG 293 (women)

Accutane: Phase III study of Accutane (oral isotrentoin) vs. observation for low-grade (CIN-1) cervical dysplasia by comparing the time to progression of CIN-1 to CIN-II, III or invasive cancer. Investigator: Ardis Moe, MD and Suzette Chafey, RN, NP

ACTG 242

Amitriptyline vs. Mexiletine for painful neuropathy.

ACTG 291

Phase II Recombinant Human Nerve Growth Factor for HIV-associated sensory neuropathy: 310.206.6414


(U-90152S) with ZDV vs. ZDV alone for Patients with CD4 200-500


(Viramune) vs. placebo, with 3TC and stable nucleoside therapy, CD4 under 200


Call UCLA to find out about this drug which blocks certain strains of HIV from penetrating immune cells.

ACTG 242

Amitriptyline vs. Mexiletine for Painful Neuropathy

ACTG 291

Phase II Recombinant Human Nerve Growth Factor for HIV - Associated Sensory Neuropathy.

ACTG 320

Phase III To determine the clinical efficacy of indinavir sulfate or placebo in combination with AZT and 3Tc in AIDS patients

HIV Epidemiology Program

Acute Infection

Conducting a study on Acute Infection. If you think you might have a recent exposure to HIV, give them a call.

  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Women Alive. It is a part of the publication Women Alive Newsletter.